Repatha Indicated to Treat Rare Type of High Cholesterol in Children
September 24, 2021Qulipta Granted FDA Approval to Prevent Migraines
September 28, 2021September 28, 2021 – Starting January 1, 2022, Eli Lilly will reduce the cost of all its non-branded insulin products. This includes the company's Insulin Lispro Injection, a non-branded alternative for Eli Lilly's Humalog®.
- Eli Lilly will lower Insulin Lispro's cost by 40% in 2022, reducing the list price to $82.41 for a single vial and $159.12 for a pack of five pre-filled pens.
- The new list prices for Insulin Lispro are 70% less than the list price for equivalent supplies of Humalog and will also apply to all other Eli Lilly non-branded insulin products.
- A drug's list price is also known as the wholesale acquisition cost (WAC). It does not necessarily reflect the net cost of a drug, which can be affected by multiple factors for both patients and plan sponsors. For instance, Eli Lilly offers a program called the Lilly Insulin Value Program that allows qualified individuals to fill insulin prescriptions at a cost of $35 for a one-month supply.